Moreover, combination of bevacizumab with inhibitory EphB4 specific monoclonal antibodies targeting the extracellular fibronectin-like domains significantly inhibited growth of HT-29 colon carcinoma xenografts more than monotherapy [82,83]. Here, EPHB4 is linked to colon carcinoma.